Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN033 in Advanced Solid Tumors
NCT06226766Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN033 in solid tumor, gastrointestinal tumor, sponsored by Alphamab Oncology. Started Jan 2024; status: terminated.
02
Drugs
JSKN033
03
Conditions
solid tumorgastrointestinal tumor
Beyond the preview
Go deeper on NCT06226766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226766.